
Preimplantation Genetic Diagnosis (PGD) Market Size, Share, and Outlook, H2-2025 Report- By Product (Reagents & Consumables, Instruments, Software and Services), By Technology (Next Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Comparative
Description
Preimplantation Genetic Diagnosis (PGD) Market Outlook
The global Preimplantation Genetic Diagnosis (PGD) Market Size is valued at $885.6 Million in 2025 and is forecast to reach $1650.4 Million in 2032 at a CAGR of 9.3%.
The Preimplantation Genetic Diagnosis (PGD) Market continue to remain a steadily growing market and offers lucrative growth opportunities across the industry stakeholders from suppliers to distributors and end-use industries. This comprehensive market research report provides 12-year historic and forecast data on Preimplantation Genetic Diagnosis (PGD) Market segments across 22 countries from 2021 to 2032. Key segments covered include By Product (Reagents & Consumables, Instruments, Software and Services), By Technology (Next Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Comparative Genomic Hybridization (CGH), Others), By Application (Aneuploidy, Structural Chromosomal Abnormalities, Single Gene Disorders, X-linked Disorders, Gender Identification, Others), offering granular insights into performance drivers and emerging patterns. With over 70 tables and charts, the report provides actionable findings based on extensive data modeling and industry surveys.
Preimplantation Genetic Diagnosis (PGD) Market Insights, 2025
The preimplantation genetic diagnosis (PGD) market is experiencing significant advancements driven by improved genetic screening technologies and increasing demand for assisted reproductive technologies. Recent developments include next-generation sequencing (NGS)-based PGD offering comprehensive chromosomal and single-gene disorder analysis with higher accuracy and faster turnaround times. Expanded panels cover a broader spectrum of hereditary diseases, allowing personalized embryo selection and reducing the risk of genetic disorders. Artificial intelligence algorithms are enhancing embryo viability assessments by integrating genetic and morphologic data. Regulatory frameworks are evolving globally to address ethical considerations, data privacy, and standardization of testing protocols. Integration with in vitro fertilization (IVF) cycles has become more streamlined through lab automation and workflow optimization. Accessibility improves with cost reductions and insurance reimbursement expansions. Research into non-invasive PGD approaches is progressing. Collaborative efforts focus on counseling services to support informed patient decisions.
Five Trends Shaping the Global Preimplantation Genetic Diagnosis (PGD) Market in 2025 and Beyond
The global Preimplantation Genetic Diagnosis (PGD) Industry is undergoing a paradigm shift driven by regulatory changes, technological innovation, and sustainability imperatives. Amidst intense demand growth from diverse end-users, companies are focusing on new product launches to cater to individual applications. Companies are also emphasizing operational resilience and circular economy principles and are aligning strategies to secure long-term growth. The report identifies key structural changes, disruptive technologies, and evolving trade flows influencing competitiveness, helping stakeholders strengthen decision-making for both the short and long term.
What are the Biggest Opportunities for Growth in the Preimplantation Genetic Diagnosis (PGD) Industry?
The Preimplantation Genetic Diagnosis (PGD) Market sector has shown strong adaptability amid volatility in prices, supply chain disruptions, and geopolitical tensions. Moving forward, potential opportunities lie in niche products, aggressive distribution activities, and digital process optimization. With increasing demand from emerging markets, Preimplantation Genetic Diagnosis (PGD) Market is positioned for growth through 2030 and beyond. This chapter provides a strategic perspective for businesses to identify revenue-generating avenues, mitigate risks, and adopt innovative pathways for expansion.
Preimplantation Genetic Diagnosis (PGD) Market Segment Insights
The Preimplantation Genetic Diagnosis (PGD) Industry offers diverse opportunities across product types, applications, and distribution channels. The analytical report provides detailed forecasts across diverse segments including By Product (Reagents & Consumables, Instruments, Software and Services), By Technology (Next Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Comparative Genomic Hybridization (CGH), Others), By Application (Aneuploidy, Structural Chromosomal Abnormalities, Single Gene Disorders, X-linked Disorders, Gender Identification, Others). Insights cover the largest and fastest-growing product types, applications, and regions, highlighting drivers behind each segment. Market outlooks are provided for five regions—Asia Pacific, North America, Europe, South America, and Middle East & Africa—with country-level forecasts for 22 markets through 2032.
Preimplantation Genetic Diagnosis (PGD) Industry Value Chain
The chapter identifies potential companies and their operations across the global Preimplantation Genetic Diagnosis (PGD) Industry ecosystem. It assists decision-makers in evaluating global Preimplantation Genetic Diagnosis (PGD) Market fundamentals, market dynamics, and disruptive trends across the value chain segments. According to the International Council of Chemical Associations (ICCA), chemicals underpin over 95% of manufactured products worldwide.
Scenario Analysis and Forecasts
Strategic planning in the Preimplantation Genetic Diagnosis (PGD) Industry requires resilience to uncertain macroeconomic and regulatory conditions. To guide stakeholders, the report offers three scenario forecasts—low growth, reference case, and high growth—enabling companies to align strategies under different market conditions.
Asia Pacific Preimplantation Genetic Diagnosis (PGD) Market Analysis – Hub of Industrial Transformation
Asia Pacific continues to be the largest and fastest-growing region for Preimplantation Genetic Diagnosis (PGD) Market, underpinned by rapid industrialization, large-scale infrastructure development, and rising consumption across emerging economies. China, India, and Southeast Asia lead the demand surge, supported by investments in chemical parks, free trade agreements, and rising domestic manufacturing capacity. China remains the single largest producer and consumer of chemicals, accounting for over $1.5 trillion in chemical sales, followed by India, which is projected by the India Brand Equity Foundation (IBEF) to become a $300 billion chemicals market by 2025. Further, Japanese and South Korean markets remain stable with most companies focusing on new product launches and diversification of sales channels.
United States Preimplantation Genetic Diagnosis (PGD) Market Insights – Innovation and Specialty Leadership
The American Chemistry Council (ACC) projects steady annual demand growth for specialty and performance chemicals, particularly in automotive, electronics, agriculture, and construction applications. The US continues to lead in specialty and high-value-added chemicals, with investments focused on R&D, advanced process technologies, and digital manufacturing. In addition, the Canadian and Mexican markets offer lucrative growth pockets for manufacturers and vendors. Focus on private-brand offerings and promotions, diversified sales channels, expansion into niche segments, adoption of advanced technologies, and sustainability are widely observed across the North American Preimplantation Genetic Diagnosis (PGD) Market.
Europe Preimplantation Genetic Diagnosis (PGD) Market Outlook 2025 – Regulatory and Innovation-Driven Growth
Europe is one of the largest markets for Preimplantation Genetic Diagnosis (PGD) Market with demand from both Western Europe and Eastern European regions increasing over the medium to long-term future. The European chemical sector employs more than 1.2 million people directly and is highly influenced by the EU Green Deal, which aims for climate neutrality by 2050. With increasing adoption of advanced technologies, raw materials, and digital transformation, Europe remains a strategic hub for Preimplantation Genetic Diagnosis (PGD) Industry competitiveness. The report analyses the key Preimplantation Genetic Diagnosis (PGD) Market drivers and opportunities across Germany, France, the United Kingdom, Spain, Italy, Russia, and other Europe.
Latin American Preimplantation Genetic Diagnosis (PGD) Market outlook rebounds in line with economic growth
Optimistic economic outlook across Brazil, Argentina, Chile, and other South and Central American countries presents strong opportunities for domestic and international Preimplantation Genetic Diagnosis (PGD) Market companies. Increased consumer spending is estimated across markets over the next few quarters through 2026. Expanding trade partnerships, urbanization, and growing demand for specialty products underpin market prospects.
Middle East and Africa Preimplantation Genetic Diagnosis (PGD) Markets- New Opportunities for Companies Harnessing Diversity
The Middle East remains a key hub for Preimplantation Genetic Diagnosis (PGD) Market companies, with Saudi Arabia, UAE, and Qatar investing heavily in distribution networks. In addition, Africa presents strong growth potential in Nigeria, South Africa, and other emerging economies, with increasing demand for cost effective and accessible products. Investment strategies tailored to localized needs and sustainable growth will be crucial for success. In addition to Nigeria, Algeria, South Africa, and other markets, steady growth markets in Ethiopia, Rwanda, Ghana, Tanzania, the Democratic Republic of Congo, and others present significant prospects for companies.
Competitive Landscape – How Preimplantation Genetic Diagnosis (PGD) Market Companies Outcompete in 2025
The ability to adapt to changing regulations, sustainability imperatives, and customer-specific innovations defines leadership in the Preimplantation Genetic Diagnosis (PGD) Market. Companies are leveraging M&A activities, strategic joint ventures, and vertical integration to secure raw material access and strengthen downstream presence. The report profiles leading players, analyzing their 2024 revenues, market shares, R&D expenditures, and strategic directions. The report analyzes Abbott Laboratories, Agilent Technologies Inc, Coopersurgical Inc, Illumina Inc, Invicta Genetics, Natera Inc, Perkinelmer Inc, Takara Bio Usa Holdings Inc, Thermo Fisher Scientific Inc, Yikon Genomics. Each company is benchmarked through a detailed SWOT and financial analysis, providing clients with insights into competitive positioning and innovation leadership.
Preimplantation Genetic Diagnosis (PGD) Market Scope
Leading Segments
By Product
Reagents & Consumables
Instruments
Software and Services
By Technology
Next Generation Sequencing (NGS)
Polymerase Chain Reaction (PCR)
Comparative Genomic Hybridization (CGH)
Others
By Application
Aneuploidy
Structural Chromosomal Abnormalities
Single Gene Disorders
X-linked Disorders
Gender Identification
Others
Leading Companies
Abbott Laboratories
Agilent Technologies Inc
Coopersurgical Inc
Illumina Inc
Invicta Genetics
Natera Inc
Perkinelmer Inc
Takara Bio Usa Holdings Inc
Thermo Fisher Scientific Inc
Yikon Genomics
Geographies
North America- US, Canada, Mexico
Europe- Germany, France, UK, Spain, Italy, Nordics, BeNeLux, Others
Asia Pacific- China, India, Japan, South Korea, Australia, South East Asia, Others
Latin America- Brazil, Argentina, Others
Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa
Reasons to Buy the Report Make informed decisions with 12-year forecasts across 22 countries and multiple market segments. Evaluate regulatory impacts, sustainability trends, and disruptive technologies shaping the chemicals industry. Gain insights into the competitive landscape, including company profiles, financials, and strategic moves. Build an integrated understanding of the chemicals ecosystem across upstream, midstream, and downstream operations. Leverage insights on circular economy initiatives, digitalization, and carbon-neutral strategies driving the next decade. Assess risks and opportunities with scenario-based forecasts tailored to different growth conditions. Access the report in multiple formats (PDF, Excel, PPT) for easier integration into strategic planning.
The global Preimplantation Genetic Diagnosis (PGD) Market Size is valued at $885.6 Million in 2025 and is forecast to reach $1650.4 Million in 2032 at a CAGR of 9.3%.
The Preimplantation Genetic Diagnosis (PGD) Market continue to remain a steadily growing market and offers lucrative growth opportunities across the industry stakeholders from suppliers to distributors and end-use industries. This comprehensive market research report provides 12-year historic and forecast data on Preimplantation Genetic Diagnosis (PGD) Market segments across 22 countries from 2021 to 2032. Key segments covered include By Product (Reagents & Consumables, Instruments, Software and Services), By Technology (Next Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Comparative Genomic Hybridization (CGH), Others), By Application (Aneuploidy, Structural Chromosomal Abnormalities, Single Gene Disorders, X-linked Disorders, Gender Identification, Others), offering granular insights into performance drivers and emerging patterns. With over 70 tables and charts, the report provides actionable findings based on extensive data modeling and industry surveys.
Preimplantation Genetic Diagnosis (PGD) Market Insights, 2025
The preimplantation genetic diagnosis (PGD) market is experiencing significant advancements driven by improved genetic screening technologies and increasing demand for assisted reproductive technologies. Recent developments include next-generation sequencing (NGS)-based PGD offering comprehensive chromosomal and single-gene disorder analysis with higher accuracy and faster turnaround times. Expanded panels cover a broader spectrum of hereditary diseases, allowing personalized embryo selection and reducing the risk of genetic disorders. Artificial intelligence algorithms are enhancing embryo viability assessments by integrating genetic and morphologic data. Regulatory frameworks are evolving globally to address ethical considerations, data privacy, and standardization of testing protocols. Integration with in vitro fertilization (IVF) cycles has become more streamlined through lab automation and workflow optimization. Accessibility improves with cost reductions and insurance reimbursement expansions. Research into non-invasive PGD approaches is progressing. Collaborative efforts focus on counseling services to support informed patient decisions.
Five Trends Shaping the Global Preimplantation Genetic Diagnosis (PGD) Market in 2025 and Beyond
The global Preimplantation Genetic Diagnosis (PGD) Industry is undergoing a paradigm shift driven by regulatory changes, technological innovation, and sustainability imperatives. Amidst intense demand growth from diverse end-users, companies are focusing on new product launches to cater to individual applications. Companies are also emphasizing operational resilience and circular economy principles and are aligning strategies to secure long-term growth. The report identifies key structural changes, disruptive technologies, and evolving trade flows influencing competitiveness, helping stakeholders strengthen decision-making for both the short and long term.
What are the Biggest Opportunities for Growth in the Preimplantation Genetic Diagnosis (PGD) Industry?
The Preimplantation Genetic Diagnosis (PGD) Market sector has shown strong adaptability amid volatility in prices, supply chain disruptions, and geopolitical tensions. Moving forward, potential opportunities lie in niche products, aggressive distribution activities, and digital process optimization. With increasing demand from emerging markets, Preimplantation Genetic Diagnosis (PGD) Market is positioned for growth through 2030 and beyond. This chapter provides a strategic perspective for businesses to identify revenue-generating avenues, mitigate risks, and adopt innovative pathways for expansion.
Preimplantation Genetic Diagnosis (PGD) Market Segment Insights
The Preimplantation Genetic Diagnosis (PGD) Industry offers diverse opportunities across product types, applications, and distribution channels. The analytical report provides detailed forecasts across diverse segments including By Product (Reagents & Consumables, Instruments, Software and Services), By Technology (Next Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Comparative Genomic Hybridization (CGH), Others), By Application (Aneuploidy, Structural Chromosomal Abnormalities, Single Gene Disorders, X-linked Disorders, Gender Identification, Others). Insights cover the largest and fastest-growing product types, applications, and regions, highlighting drivers behind each segment. Market outlooks are provided for five regions—Asia Pacific, North America, Europe, South America, and Middle East & Africa—with country-level forecasts for 22 markets through 2032.
Preimplantation Genetic Diagnosis (PGD) Industry Value Chain
The chapter identifies potential companies and their operations across the global Preimplantation Genetic Diagnosis (PGD) Industry ecosystem. It assists decision-makers in evaluating global Preimplantation Genetic Diagnosis (PGD) Market fundamentals, market dynamics, and disruptive trends across the value chain segments. According to the International Council of Chemical Associations (ICCA), chemicals underpin over 95% of manufactured products worldwide.
Scenario Analysis and Forecasts
Strategic planning in the Preimplantation Genetic Diagnosis (PGD) Industry requires resilience to uncertain macroeconomic and regulatory conditions. To guide stakeholders, the report offers three scenario forecasts—low growth, reference case, and high growth—enabling companies to align strategies under different market conditions.
Asia Pacific Preimplantation Genetic Diagnosis (PGD) Market Analysis – Hub of Industrial Transformation
Asia Pacific continues to be the largest and fastest-growing region for Preimplantation Genetic Diagnosis (PGD) Market, underpinned by rapid industrialization, large-scale infrastructure development, and rising consumption across emerging economies. China, India, and Southeast Asia lead the demand surge, supported by investments in chemical parks, free trade agreements, and rising domestic manufacturing capacity. China remains the single largest producer and consumer of chemicals, accounting for over $1.5 trillion in chemical sales, followed by India, which is projected by the India Brand Equity Foundation (IBEF) to become a $300 billion chemicals market by 2025. Further, Japanese and South Korean markets remain stable with most companies focusing on new product launches and diversification of sales channels.
United States Preimplantation Genetic Diagnosis (PGD) Market Insights – Innovation and Specialty Leadership
The American Chemistry Council (ACC) projects steady annual demand growth for specialty and performance chemicals, particularly in automotive, electronics, agriculture, and construction applications. The US continues to lead in specialty and high-value-added chemicals, with investments focused on R&D, advanced process technologies, and digital manufacturing. In addition, the Canadian and Mexican markets offer lucrative growth pockets for manufacturers and vendors. Focus on private-brand offerings and promotions, diversified sales channels, expansion into niche segments, adoption of advanced technologies, and sustainability are widely observed across the North American Preimplantation Genetic Diagnosis (PGD) Market.
Europe Preimplantation Genetic Diagnosis (PGD) Market Outlook 2025 – Regulatory and Innovation-Driven Growth
Europe is one of the largest markets for Preimplantation Genetic Diagnosis (PGD) Market with demand from both Western Europe and Eastern European regions increasing over the medium to long-term future. The European chemical sector employs more than 1.2 million people directly and is highly influenced by the EU Green Deal, which aims for climate neutrality by 2050. With increasing adoption of advanced technologies, raw materials, and digital transformation, Europe remains a strategic hub for Preimplantation Genetic Diagnosis (PGD) Industry competitiveness. The report analyses the key Preimplantation Genetic Diagnosis (PGD) Market drivers and opportunities across Germany, France, the United Kingdom, Spain, Italy, Russia, and other Europe.
Latin American Preimplantation Genetic Diagnosis (PGD) Market outlook rebounds in line with economic growth
Optimistic economic outlook across Brazil, Argentina, Chile, and other South and Central American countries presents strong opportunities for domestic and international Preimplantation Genetic Diagnosis (PGD) Market companies. Increased consumer spending is estimated across markets over the next few quarters through 2026. Expanding trade partnerships, urbanization, and growing demand for specialty products underpin market prospects.
Middle East and Africa Preimplantation Genetic Diagnosis (PGD) Markets- New Opportunities for Companies Harnessing Diversity
The Middle East remains a key hub for Preimplantation Genetic Diagnosis (PGD) Market companies, with Saudi Arabia, UAE, and Qatar investing heavily in distribution networks. In addition, Africa presents strong growth potential in Nigeria, South Africa, and other emerging economies, with increasing demand for cost effective and accessible products. Investment strategies tailored to localized needs and sustainable growth will be crucial for success. In addition to Nigeria, Algeria, South Africa, and other markets, steady growth markets in Ethiopia, Rwanda, Ghana, Tanzania, the Democratic Republic of Congo, and others present significant prospects for companies.
Competitive Landscape – How Preimplantation Genetic Diagnosis (PGD) Market Companies Outcompete in 2025
The ability to adapt to changing regulations, sustainability imperatives, and customer-specific innovations defines leadership in the Preimplantation Genetic Diagnosis (PGD) Market. Companies are leveraging M&A activities, strategic joint ventures, and vertical integration to secure raw material access and strengthen downstream presence. The report profiles leading players, analyzing their 2024 revenues, market shares, R&D expenditures, and strategic directions. The report analyzes Abbott Laboratories, Agilent Technologies Inc, Coopersurgical Inc, Illumina Inc, Invicta Genetics, Natera Inc, Perkinelmer Inc, Takara Bio Usa Holdings Inc, Thermo Fisher Scientific Inc, Yikon Genomics. Each company is benchmarked through a detailed SWOT and financial analysis, providing clients with insights into competitive positioning and innovation leadership.
Preimplantation Genetic Diagnosis (PGD) Market Scope
Leading Segments
By Product
Reagents & Consumables
Instruments
Software and Services
By Technology
Next Generation Sequencing (NGS)
Polymerase Chain Reaction (PCR)
Comparative Genomic Hybridization (CGH)
Others
By Application
Aneuploidy
Structural Chromosomal Abnormalities
Single Gene Disorders
X-linked Disorders
Gender Identification
Others
Leading Companies
Abbott Laboratories
Agilent Technologies Inc
Coopersurgical Inc
Illumina Inc
Invicta Genetics
Natera Inc
Perkinelmer Inc
Takara Bio Usa Holdings Inc
Thermo Fisher Scientific Inc
Yikon Genomics
Geographies
North America- US, Canada, Mexico
Europe- Germany, France, UK, Spain, Italy, Nordics, BeNeLux, Others
Asia Pacific- China, India, Japan, South Korea, Australia, South East Asia, Others
Latin America- Brazil, Argentina, Others
Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa
Reasons to Buy the Report
Table of Contents
182 Pages
- 1. Table of Contents
- List of Figures and Tables
- 2. Executive Summary
- 2.1 Key Highlights
- 2.1.1 Preimplantation Genetic Diagnosis (PGD) Market Size Outlook, 2018-2024 and 2025-2032
- 2.1.2 Largest Preimplantation Genetic Diagnosis (PGD) Market Types and Applications
- 2.1.3 Fastest Growing Segments
- 2.1.4 Potential Markets
- 2.1.5 Market Concentration
- 2.2 Market Scope and Segmentation
- 2.2.1 Market Scope- Segments
- 2.2.2 Market Scope- Countries
- 2.2.3 Macroeconomic and Demographic Outlook
- 2.2.4 Abbreviations
- 2.2.5 Units and Currency Conversions
- 3. Research Methodology
- 3.1 Primary Research Surveys
- 3.2 Secondary Data Sources
- 3.3 Data Triangulation
- 3.4 Forecast Methodology
- 3.5 Assumptions and Limitations
- 4. Introduction to Global Preimplantation Genetic Diagnosis (PGD) Market in 2025
- 4.1 Industry Panorama
- 4.2 Leading Companies Profiled in the Study
- 4.3 Asia Pacific Markets offer Robust Market Prospects for New Entrants
- 4.4 Market Dynamics
- 4.4.1 Market Dynamics- Trends and Drivers
- 4.4.2 Market Dynamics- Opportunities and Challenges
- 4.5 Regional Analysis
- 4.6 Porter’s Five Force Analysis
- 4.6.1 Intensity of Competitive Rivalry
- 4.6.2 Threat of New Entrants
- 4.6.3 Threat of Substitutes
- 4.6.4 Bargaining Power of Buyers
- 4.6.5 Bargaining Power of Suppliers
- 4.7 Preimplantation Genetic Diagnosis (PGD) Market Industry Value Chain Analysis
- 4.7.1 Stage of Value Chain
- 4.7.2 Key Activities of Companies
- 4.7.3 Companies Included in Each Stage
- 4.7.4 Key Insights
- 5. Preimplantation Genetic Diagnosis (PGD) Market Outlook to 2032
- 5.1 Market Size Forecast by Type, 2021-2024 and 2025-2032
- 5.2 Market Size Forecast by Application, 2021-2024 and 2024-2032
- 5.3 Market Size Forecast by Geography, 2021-2024 and 2024-2032
- By Product
- Reagents & Consumables
- Instruments
- Software and Services
- By Technology
- Next Generation Sequencing (NGS)
- Polymerase Chain Reaction (PCR)
- Comparative Genomic Hybridization (CGH)
- Others
- By Application
- Aneuploidy
- Structural Chromosomal Abnormalities
- Single Gene Disorders
- X-linked Disorders
- Gender Identification
- Others
- 6. Global Preimplantation Genetic Diagnosis (PGD) Market Outlook across Growth Scenarios
- 6.1 Low Growth Scenario
- 6.2 Base/Reference Case
- 6.3 High Growth Scenario
- 6. North America Preimplantation Genetic Diagnosis (PGD) Market Size Outlook
- 6.1 Key Market Statistics, 2024
- 6.2 North America Preimplantation Genetic Diagnosis (PGD) Market Trends and Growth Opportunities
- 6.2.1 North America Preimplantation Genetic Diagnosis (PGD) Market Outlook by Type
- 6.2.2 North America Preimplantation Genetic Diagnosis (PGD) Market Outlook by Application
- 6.3 North America Preimplantation Genetic Diagnosis (PGD) Market Outlook by Country
- 6.3.1 The US Preimplantation Genetic Diagnosis (PGD) Market Outlook, 2021- 2032
- 6.3.2 Canada Preimplantation Genetic Diagnosis (PGD) Market Outlook, 2021- 2032
- 6.3.3 Mexico Preimplantation Genetic Diagnosis (PGD) Market Outlook, 2021- 2032
- 7. Europe Preimplantation Genetic Diagnosis (PGD) Market Size Outlook
- 7.1 Key Market Statistics, 2024
- 7.2 Europe Preimplantation Genetic Diagnosis (PGD) Market Trends and Growth Opportunities
- 7.2.1 Europe Preimplantation Genetic Diagnosis (PGD) Market Outlook by Type
- 7.2.2 Europe Preimplantation Genetic Diagnosis (PGD) Market Outlook by Application
- 7.3 Europe Preimplantation Genetic Diagnosis (PGD) Market Outlook by Country
- 7.3.2 Germany Preimplantation Genetic Diagnosis (PGD) Market Outlook, 2021- 2032
- 7.3.3 France Preimplantation Genetic Diagnosis (PGD) Market Outlook, 2021- 2032
- 7.3.4 The UK Preimplantation Genetic Diagnosis (PGD) Market Outlook, 2021- 2032
- 7.3.5 Spain Preimplantation Genetic Diagnosis (PGD) Market Outlook, 2021- 2032
- 7.3.6 Italy Preimplantation Genetic Diagnosis (PGD) Market Outlook, 2021- 2032
- 7.3.7 Russia Preimplantation Genetic Diagnosis (PGD) Market Outlook, 2021- 2032
- 7.3.8 Rest of Europe Preimplantation Genetic Diagnosis (PGD) Market Outlook, 2021- 2032
- 8. Asia Pacific Preimplantation Genetic Diagnosis (PGD) Market Size Outlook
- 8.1 Key Market Statistics, 2024
- 8.2 Asia Pacific Preimplantation Genetic Diagnosis (PGD) Market Trends and Growth Opportunities
- 8.2.1 Asia Pacific Preimplantation Genetic Diagnosis (PGD) Market Outlook by Type
- 8.2.2 Asia Pacific Preimplantation Genetic Diagnosis (PGD) Market Outlook by Application
- 8.3 Asia Pacific Preimplantation Genetic Diagnosis (PGD) Market Outlook by Country
- 8.3.1 China Preimplantation Genetic Diagnosis (PGD) Market Outlook, 2021- 2032
- 8.3.2 India Preimplantation Genetic Diagnosis (PGD) Market Outlook, 2021- 2032
- 8.3.3 Japan Preimplantation Genetic Diagnosis (PGD) Market Outlook, 2021- 2032
- 8.3.4 South Korea Preimplantation Genetic Diagnosis (PGD) Market Outlook, 2021- 2032
- 8.3.5 Australia Preimplantation Genetic Diagnosis (PGD) Market Outlook, 2021- 2032
- 8.3.6 South East Asia Preimplantation Genetic Diagnosis (PGD) Market Outlook, 2021- 2032
- 8.3.7 Rest of Asia Pacific Preimplantation Genetic Diagnosis (PGD) Market Outlook, 2021- 2032
- 9. South America Preimplantation Genetic Diagnosis (PGD) Market Size Outlook
- 9.1 Key Market Statistics, 2024
- 9.2 South America Preimplantation Genetic Diagnosis (PGD) Market Trends and Growth Opportunities
- 9.2.1 South America Preimplantation Genetic Diagnosis (PGD) Market Outlook by Type
- 9.2.2 South America Preimplantation Genetic Diagnosis (PGD) Market Outlook by Application
- 9.3 South America Preimplantation Genetic Diagnosis (PGD) Market Outlook by Country
- 9.3.1 Brazil Preimplantation Genetic Diagnosis (PGD) Market Outlook, 2021- 2032
- 9.3.2 Argentina Preimplantation Genetic Diagnosis (PGD) Market Outlook, 2021- 2032
- 9.3.3 Rest of South and Central America Preimplantation Genetic Diagnosis (PGD) Market Outlook, 2021- 2032
- 10. Middle East and Africa Preimplantation Genetic Diagnosis (PGD) Market Size Outlook
- 10.1 Key Market Statistics, 2024
- 10.2 Middle East and Africa Preimplantation Genetic Diagnosis (PGD) Market Trends and Growth Opportunities
- 10.2.1 Middle East and Africa Preimplantation Genetic Diagnosis (PGD) Market Outlook by Type
- 10.2.2 Middle East and Africa Preimplantation Genetic Diagnosis (PGD) Market Outlook by Application
- 10.3 Middle East and Africa Preimplantation Genetic Diagnosis (PGD) Market Outlook by Country
- 10.3.1 Saudi Arabia Preimplantation Genetic Diagnosis (PGD) Market Outlook, 2021- 2032
- 10.3.2 The UAE Preimplantation Genetic Diagnosis (PGD) Market Outlook, 2021- 2032
- 10.3.3 Rest of Middle East Preimplantation Genetic Diagnosis (PGD) Market Outlook, 2021- 2032
- 10.3.4 South Africa Preimplantation Genetic Diagnosis (PGD) Market Outlook, 2021- 2032
- 10.3.5 Egypt Preimplantation Genetic Diagnosis (PGD) Market Outlook, 2021- 2032
- 10.3.6 Rest of Africa Preimplantation Genetic Diagnosis (PGD) Market Outlook, 2021- 2032
- 11. Company Profiles
- 11.1 Leading 10 Companies
- Abbott Laboratories
- Agilent Technologies Inc
- Coopersurgical Inc
- Illumina Inc
- Invicta Genetics
- Natera Inc
- Perkinelmer Inc
- Takara Bio Usa Holdings Inc
- Thermo Fisher Scientific Inc
- Yikon Genomics
- 11.2 Overview
- 11.3 Products and Services
- 11.4 SWOT Profile
- 12. Appendix
- 12.1 Subscription Options
- 12.2 Customization Options
- 12.3 Publisher Details
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.